Drug research

Sonelokimab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as M1095

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugNCT06641076	MoonLake Immunotherapeutics AG	Phase 3	Active not recruiting	2027-02-04Estimated
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseNCT06641089	MoonLake Immunotherapeutics AG	Phase 3	Recruiting	2027-01-15Estimated
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411379	MoonLake Immunotherapeutics AG	Phase 3	Completed	2025-08-14Actual
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaNCT07007637	MoonLake Immunotherapeutics AG	Phase 3	Enrolling by invitation	2028-06-13Estimated
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)NCT06768671	MoonLake Immunotherapeutics AG	Phase 3	Active not recruiting	2026-09-28Estimated
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisNCT07223138	MoonLake Immunotherapeutics AG	Phase 3	Enrolling by invitation	2028-02-04Estimated
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411899	MoonLake Immunotherapeutics AG	Phase 3	Completed	2025-09-02Actual
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisNCT05640245	MoonLake Immunotherapeutics AG	Phase 2	Completed	2023-09-05Actual

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

MoonLake Immunotherapeutics AGActive not recruitingPrimary completion: 2027-02-04 · Estimated

Trial details

Registry ID: NCT06641076
Phase: Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

MoonLake Immunotherapeutics AGRecruitingPrimary completion: 2027-01-15 · Estimated

Trial details

Registry ID: NCT06641089
Phase: Phase 3

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

MoonLake Immunotherapeutics AGCompletedPrimary completion: 2025-08-14 · Actual

Trial details

Registry ID: NCT06411379
Phase: Phase 3

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

MoonLake Immunotherapeutics AGEnrolling by invitationPrimary completion: 2028-06-13 · Estimated

Trial details

Registry ID: NCT07007637
Phase: Phase 3

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

MoonLake Immunotherapeutics AGActive not recruitingPrimary completion: 2026-09-28 · Estimated

Trial details

Registry ID: NCT06768671
Phase: Phase 3

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

MoonLake Immunotherapeutics AGEnrolling by invitationPrimary completion: 2028-02-04 · Estimated

Trial details

Registry ID: NCT07223138
Phase: Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

MoonLake Immunotherapeutics AGCompletedPrimary completion: 2025-09-02 · Actual

Trial details

Registry ID: NCT06411899
Phase: Phase 3

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

MoonLake Immunotherapeutics AGCompletedPrimary completion: 2023-09-05 · Actual

Trial details

Registry ID: NCT05640245
Phase: Phase 2

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.